Latest Breaking News On - Franchise communicationsoncology - Page 1 : comparemela.com

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI

Investigational Onivyde (irinotecan liposome injection) in the NALIRIFOX treatment regimen demonstrated statistically significant improvements in overall survival and progression-free survival compared

United statesFrance generalT ai peiUnited kingdomSan franciscoZev wainbergHoward mayerElizabeth kalinaIpsen euronextUcla gi oncology programHead of researchAmerican society of clinical oncologyDrug administrationDevelopment for ipsenDrug administration for onivydeCommunications patient advocacy

Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atez

The trial did not meet its primary endpoint of overall survival (OS)The safety profile of the combination of cabozantinib and atezolizumab was consistent with the known safety profiles for each single agentThe clinical trial results will be presented at a future medical meetingPARIS (BUSINESS WIRE) Regulatory News.

France generalUnited statesUnited kingdomHoward mayerIoana piscociuIpsen euronextHead of researchEuropean unionTakeda pharmaceutical company limitedRegulatory newsExecutive vice presidentBoth ipsenRare diseaseWith specialty careSponsored leveli american depositary receiptFrench autorit

Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy

The trial did not meet its primary endpoint of overall survival (OS) The safety profile of the combination of cabozantinib and atezolizumab was consistent with the known safety profiles for

France generalUnited statesUnited kingdomHoward mayerIoana piscociuIpsen euronextHead of researchEuropean unionTakeda pharmaceutical company limitedExecutive vice presidentBoth ipsenRare diseaseWith specialty careSponsored leveli american depositary receiptForward looking statementsFrench autorit

Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc to 11 August 2022

Extension allows for satisfaction of the HSR Condition as outlined in the Merger Agreement Epizyme stockholders are encouraged to tender their shares to the offer today Regulatory News: Ipsen

France generalUnited kingdomUnited statesIpsen sa euronextIoana piscociuComputershare trust companyExchange commissionIpsen biopharmaceuticals incHibernia merger sub incEpizyme incHibernia merger subHart scott rodino antitrust improvements actTrust companyTender offer statementIpsen biopharmaceuticalsIpsen pharma

Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer

Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesUnited kingdomHong kongNew zealandWorld health organizationAl qahirahSouth koreaDominican republicSaudi arabiaGreat britainRussian federationMon junHoward mayerIpsen euronextHead of research